Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status Prescription
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 0069-8141; 53869-2231; 68724-1020; 0069-8140; 72969-115; 53869-2230
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Colitis ischaemic24.04.08.012; 07.08.01.0040.000208%Not Available
Colon cancer16.13.01.001; 07.21.01.001--Not Available
Coma17.02.09.001--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Congenital renal cyst20.01.04.007; 16.27.01.003; 03.06.01.005--Not Available
Constipation07.02.02.0010.035965%
Cough22.02.03.0010.012788%
Creatinine renal clearance decreased13.13.01.0130.000533%Not Available
Cyst16.02.02.002; 08.03.05.0010.000533%Not Available
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.001--Not Available
Death08.04.01.0010.052054%
Dehydration14.05.05.0010.007726%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.001--Not Available
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.0010.075394%
Diplopia17.17.01.005; 06.02.06.0020.006927%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000347%
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.001332%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 20 Pages